The Conversation (0)
Bloomberg reports that Roche Holding AG (ROG)’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
Bloomberg reports that Roche Holding AG (ROG)’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
As quoted in the market news:
Combined with chemotherapy, the drug, GA101, shrank tumors in 76 percent of patients with chronic lymphocytic leukemia compared with 30 percent for those getting just chemotherapy, according to a summary of the 589-patient trial. The results will be presented at the American Society of Clinical Oncology’s meeting starting May 31 in Chicago.